Journal article icon

Journal article

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Abstract:

Background

The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 studies of patients with PsA were used to evaluate the effect of tofacitinib on composite endpoints.

Methods

Oral Psoriatic Arthritis triaL (OPAL) Broaden was a 12-month study of tumor necrosis factor i...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1186/s13075-018-1739-0

Authors


Helliwell, P More by this author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Subgroup:
Botnar Research Centre
ORCID:
0000-0002-4756-663X
Fitzgerald, O More by this author
Soriano, ER More by this author
Expand authors...
Pfizer Inc. More from this funder
Publisher:
BioMed Central Publisher's website
Journal:
Arthritis Research and Therapy Journal website
Volume:
20
Pages:
242
Publication date:
2018-10-29
Acceptance date:
2018-10-01
DOI:
EISSN:
1478-6362
ISSN:
1478-6354
Pubs id:
pubs:923364
URN:
uri:13f83d82-62d9-4b5a-85e4-d0af6b43d139
UUID:
uuid:13f83d82-62d9-4b5a-85e4-d0af6b43d139
Local pid:
pubs:923364

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP